From: STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma
Model | Variable | P-value | Hazard ratio |
---|---|---|---|
(95% CI) | |||
A. Clinical pathology and STAG2 | STAG2 (< 95%) | 0.017 | 1.421 (1.064-1.898) |
T stage (1/2) | 0.729 | 1.066 (0.743-1.529) | |
N stage (N0) | 0.196 | 0.826 (0.618-1.104) | |
Grade (1/2) | 0.013 | 0.711 (0.544-0.93) | |
Sex (female) | 0.865 | 1.023 (0.785-1.333) | |
Margin involvement (negative) | 0.297 | 0.852 (0.63-1.151) | |
M stage (M0) | 0.132 | 1.487 (0.887-2.492) | |
B. Clinical pathology and STAG2 | STAG2 (< 95%) | 0.017 | 1.415 (1.064-1.883) |
T stage (1/2) | 0.719 | 1.068 (0.746-1.531) | |
N stage (N0) | 0.195 | 0.825 (0.618-1.103) | |
Grade (1/2) | 0.013 | 0.713 (0.546-0.931) | |
Margin involvement (negative) | 0.3 | 0.853 (0.631-1.152) | |
M stage (M0) | 0.126 | 1.494 (0.894-2.497) | |
C. Clinical pathology and STAG2 | STAG2 (< 95%) | 0.016 | 1.42 (1.068-1.888) |
N stage (N0) | 0.198 | 0.827 (0.619-1.105) | |
Grade (1/2) | 0.014 | 0.717 (0.55-0.934) | |
Margin involvement (negative) | 0.321 | 0.861 (0.64-1.158) | |
M stage (M0) | 0.131 | 1.484 (0.889-2.478) | |
D. Clinical pathology and STAG2 | STAG2 (< 95%) | 0.014 | 1.428 (1.074-1.898) |
N stage (N0) | 0.185 | 0.822 (0.616-1.098) | |
Grade (1/2) | 0.011 | 0.709 (0.545-0.924) | |
M stage (M0) | 0.086 | 1.556 (0.94-2.574) | |
E. Clinical pathology and STAG2 (final model) | STAG2 (< 95%) | 0.021 | 1.394 (1.051-1.849) |
Grade (1/2) | 0.007 | 0.697 (0.536-0.906) | |
M stage (M0) | 0.061 | 1.615 (0.979-2.665) |